Pustular psoriasis

This study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…

This study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …

This phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…

This study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…

This study looks at how well tildrakizumab works for psoriasis in areas that are often hard to treat, like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive tildrakizumab and be followed for up to 52 weeks. The goal is to see i…

This study looked at 81 adults with either palmoplantar psoriasis or palmoplantar eczema, two skin conditions that can look very similar on the palms and soles. Researchers used two special camera techniques—polarized dermoscopy and ultraviolet-induced fluorescence dermoscopy—to …